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Background: The aim of this study was to investigate the long-term limb salvage rate and
overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and
melphalan for locally advanced soft tissue sarcoma (STS).
Methods: From 1991 to 2003, 73 patients (36 men, 37 women, median age 54 [range 14–80]
years) with biopsy-proven STS underwent 77 perfusions followed by delayed surgical resec-
tion, with or without adjuvant radiation. Limb salvage and overall survival curves were
calculated by the Kaplan-Meier method.
Results: A total of 21 amputations (28%) were performed. Overall 1, 5, and 10 years limb
salvage was 80.1% ± 4.8%, 68.2% ± 6.5%, and 60.6% ± 9.2%, respectively. We found that
the risk of amputation was linked to three time periods. The ﬁrst was within a year after
perfusion, mainly as a result of massive necrosis of the tumor and overlying skin, resulting in
soft tissue deﬁcit or recurrent disease (n = 17). The second was within 5 years, with two
amputations performed for late local recurrence. The third occurred 10 years after perfusion,
with two amputations performed for critical leg ischemia. Another two patients developed a
pathological fracture of the femur due to radiation osteonecrosis. These four patients received
adjuvant radiotherapy. Overall, 1, 5, and 10 years survival was 82.9% ± 9.2%,
58.7% ± 13.1%, and 42.5% ± 18.2%, respectively.
Conclusions: ILP treatment with tumor necrosis factor alpha and melphalan followed by
delayed surgical resection and adjuvant radiation treatment is an effective limb salvage
treatment regimen for locally advanced STS. However, we observed late morbidity, with two
amputations performed for critical leg ischemia and two pathological fractures of the femur in
patients receiving adjuvant radiotherapy.
Key Words: Isolated limb perfusion—Sarcoma—Tumor necrosis factor alpha—Melphalan
—Radiotherapy—Amputation—Late morbidity.
Limb salvage in patients with locally advanced
extremity soft tissue sarcoma (STS) continues to be a
challenge. Survival in these patients is determined by
the development of distant metastases and is not
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1499improved with the amputation of the aﬀected limb.
1,2
Besides amputation, an extensive surgical procedure
followed by radiotherapy is a treatment option.
3
Rosenberg et al.
1 showed the same disease-free and
overall survival as amputation in the early 1980s with
this treatment regimen. Preoperative therapies to
improve limb salvage rates have been proposed. Suit
et al.
4 reported in 1981 on the use of preoperative
radiotherapy. Eilber et al.
2,5 combined preopera-
tive (intra-arterial or systemic) chemotherapy and
radiotherapy to improve resectability rates. In a
randomized trial, OSullivan et al.
6 reported a greater
risk of wound complications in the preoperative
radiotherapy group compared with the postoperative
radiotherapy group. The use of brachytherapy may
also improve local control and avoid amputation.
7
The current treatment strategy of high-grade limb
sarcomas is wide local resection, with the goal of
achieving a R0 resection with a 2-cm margin. If the
margin is < 2 cm or if a R1 resection (microscopi-
cally involved margin) is performed, adjuvant radio-
therapy with 50–70 Gy is indicated to reduce the risk
of local failure.
3 The question whether radiotherapy
should be given before or after surgery is still unan-
swered.
6
Another strategy for limb salvage in locally
advanced extremity STS is to perform an isolated
limb perfusion (ILP) with cytostatic agents. This
procedure, which was originally developed for the
treatment of melanoma of the limb in 1957, was also
applied to the treatment of STS of the limb. In their
ﬁrst experience, Krementz et al.
8 showed an early
response rate of 83% with melphalan alone; however,
complete regression of the tumor was rarely seen.
Other perfusion agents in the treatment of limb STS
were therefore investigated. Rossi et al.
9 claimed that
doxorubicin was efﬁcacious; another study
10 showed
that doxorubicin alone was ineffective and that
combined with melphalan, it was too toxic. Cisplatin
also proved to be less effective than melphalan in the
limb perfusion setting of sarcomas, and carboplatin
was too neurotoxic.
11–13
With the addition of tumor necrosis factor alpha
(TNF-a) to the perfusion circuit, Lienard et al.
14
made a step forward in the treatment of locally
advanced extremity STS. A large European multi-
center study proved the ILP concept in the limb
salvage procedures for locally advanced STS with
TNF-a and melphalan. The objective response rate
was 75%, and a limb salvage rate of 82% was
achieved with minimal treatment-related morbidity.
15
Since 1991, patients with locally advanced STS of the
limbs have been treated at the University Medical
Center Groningen by ILP with TNF-a and melpha-
lan with or without interferon gamma as perfusion
agents, followed by delayed surgical excision and
postoperative radiotherapy if a marginal resection or
nonradical resection was performed. Recently we
encountered long-term local morbidity, and therefore
the aim of the present study was to analyze the limb
salvage rate and survival in patients with locally ad-
vanced STS of the extremities that were treated in our
center and to report the late effects of this treatment
modality.
PATIENTS AND METHODS
Patient Characteristics
During 1991–2003, a total of 73 patients with STS
of the extremity underwent 77 perfusions with a
combination of TNF-a and melphalan, with
(n = 19) or without (n = 58) interferon gamma.
Thirty-six men and 37 women with a median age of
54 (range 14–80) years were treated. Tumors were
considered unresectable because of size, their multi-
centricity in the limb, or fixation to the neurovascular
bundle and/or bone, and therefore amputation was
the only treatment option. Perfusion was performed
at the iliac level in 32 cases (42%), at the popliteal
level in 23 cases (30%), and at the femoral and
axillary level in 11 cases each (14%). There were 60
primary (82%) and 13 recurrent (18%) sarcomas.
Sixty-two sarcomas were located in the leg (85%)a n d
11 were located in the arm (15%). All patients were
treated after informed consent was obtained accord-
ing to institutional guidelines. Nineteen different
histological types of STS were distinguished. The
pathological grade of the tumor was scored following
the criteria of Coindre et al.,
17 and the stage of the
tumor was scored according to the American Joint
Committee on Cancer (AJCC) criteria
16 (Table 1).
Median tumor size was 16.2 (range 8.3–23) cm. In
case of multifocal disease, the largest diameter was
used.
Perfusion Technique
The perfusion technique used at the University
Medical Center Groningen is based on the tech-
nique developed by Creech et al.
18 and described
elsewhere.
19 The major modiﬁcations during the last
30 years were the use of modern thermal blankets,
improvement in leakage monitoring, and the intro-
duction of a membrane oxygenator and heat
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Because extensive washing with 6 L of saline is used,
systemic inflammatory response syndrome (SIRS) is
rarely seen.
20 After surgery, patients can be moni-
tored on the recovery ward instead of the intensive
care unit.
Assessment of Tumor Response, Tumor Remnant, and
Follow-up
Responses were assessed by standardized World
Health Organization criteria and on the basis of
physical examination and/or imaging investigations
(magnetic resonance imaging and computed tomo-
graphic scans).
21 Complete response was deﬁned as
the disappearance of all measurable disease in the
limb for > 4 weeks, partial response as regression of
the tumor size by > 50% of the largest diameter
for > 4 weeks, and no change as regression
of < 50% of the tumor in the limb or progression
of < 25% for longer than 4 weeks. Resection of the
tumor remnants was performed 2–15 weeks (median,
8 weeks) after perfusion. After resection, response
was also assessed by pathological examination. The
tumor remnants were measured in three dimensions
and the percentage of necrosis estimated in relation to
the complete tumor volume. Representative tumor
sections were taken, encompassing macroscopi-
cally different tumor areas, including necrosis. As a
general rule, one section per centimeter largest
diameter with a minimum of three was taken. On the
basis of an integration of gross and microscopic
findings, a final estimate of the percentages of viable
and necrotic or regressive tumor was made.
Excision margins were also evaluated on patho-
logical examination and classiﬁed as radical when the
resection margins were free of tumor cells (complete
resection, R0), as R1 when resection margins were
microscopically involved, or as R2 when resection
margins were macroscopically positive involved.
Postoperative radiotherapy (60–70 Gy) was consid-
ered indicated in case of < 95% necrosis on patho-
logical examination of the tumor or with marginal
or microscopically positive resection margins. All
patients were followed after perfusion treatment in a
standardized protocol. Median follow-up was 27
(range 2–138) months.
Statistical Analysis
Survival and limb salvage curves were calculated
according to the Kaplan-Meier method and log rank
test.
22 Values of P < 0.05 were considered to be
statistically signiﬁcant. GraphPad Prism version 2.0
for Windows statistical software was used.
RESULTS
Tumor Response
A clinical complete response was observed after 19
ILPs (25%), a partial response after 53 ILPs (69%),
and no change after 5 ILPs (6%); local progression
was never observed. Resection of the remnant tumor
was performed in 68 patients (93%). The pathological
response is illustrated in Fig. 1. After 17 ILPs (23%),
no viable tumor cells were found on pathological
examination. In 29 ILPs (37%), ‡ 90% necrosis was
found on pathological examination. When both
groups were added together, a good response to ILP
was found in 60% of the patients. In 17 ILPs (22%),
an intermediate response was found on pathological
examination (necrosis 50%–80%). After eight ILPs
(10%), < 20% of necrosis or no necrosis was found
on pathological examination. In five patients (7%),
FIG. 1. Percentage of necrosis estimated at pathological exami-
nation of resected tumor remnant in relation to number of patients.
TABLE 1. Histological grade and stage of tumors
a
Characteristic n %
Grade
I1 0 1 4
II 23 32
III 40 54
Stage
I1 0 1 4
II 1 1
III 50 69
IV 12 16
a Grade according to Coindre et al.,
17 and stage according to
American Joint Committee on Cancer.
16
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gression of distant metastases in four patients and a
local recurrence in one patient that necessitated a
second perfusion, resulting in 90% necrosis of
the tumor. No correlation could be demonstrated
between grade and percentage of tumor necrosis after
perfusion (Pearsons correlation). Postoperative
radiotherapy (total dose 60–70 Gy, 25 · 2 Gy daily
and 10–20 Gy boost) was given in 37 patients with
microscopically involved or marginally free resection
margins. Radiotherapy was initiated within 5–6
weeks after tumor resection. Radiation treatment was
delivered through a multiple-field technique with
computed tomographic treatment planning on a
linear accelerator, 6–15 MV.
Amputations and Limb Salvage
A total of 21 amputations (28%) were performed.
Table 2 presents the time interval between ILP and
amputation and the rationale for amputation. Overall
1, 5, and 10 years limb salvage was 80.1% ± 4.8%,
68.2% ± 6.5%, and 60.6% ± 9.2%, respectively
(Fig. 2). When we analyzed the limb salvage curve,
we found that the risk for amputation could be
divided into three time episodes. The ﬁrst period
occurs within the ﬁrst year or year and a half after
perfusion (n = 17 patients), with amputation per-
formed to treat massive perfusion-induced necrosis of
the tumor and overlying skin, which resulted in a soft
tissue deﬁcit (n = 6); tumor recurrence after perfu-
sion (n = 5); wound complications after ILP fol-
lowed by radiotherapy (n = 2); a microscopically
involved resection margin with the rejection of the
patient for adjuvant radiotherapy of the foot
(n = 2); insufﬁcient clinical response (one patient);
TABLE 2. Amputations performed in 21 patients according to interval duration
Patient
no. Diagnosis
Age
(y)
Interval
(mo) Resection RT
Rationale for
amputation Current status
1 PUS 60 0 R0 No Postperfusion necrosis38 NED 120 months
2 Angiosarcoma 74 1 R2 No Local recurrence DOD 11 months
3 Fibrosarcoma 76 1 R0 No Postperfusion necrosis NED 2 months
4 PUS 67 2 R0 No Postperfusion necrosis DOD 9 months
5 Epithelioid Sarcoma 21 2 R0 No Postperfusion necrosis DOD 54 months
6 Leiomyosarcoma 17 2 R0 No Insufﬁcient clinical response DOD 7 months
7 Liposarcoma 60 2 R1 No R1 resection, RT not possible AWD 10 months
8 PNET 62 3 R0 No Local recurrence DOD 17 months
9 Synovial sarcoma 39 3 R0 No Postperfusion necrosis DOD 50 months
10 PUS 63 3 R1 No Postperfusion necrosis NED 72 months
11 Angiosarcoma 80 4 R1 No Local recurrence DOD 10 months
12 Synovial sarcoma 65 4 R1 No R1 resection, RT not possible NED 6 months
13 Epithelioid Sarcoma 22 6 R2 No Local recurrence
a DOD 39 months
14 Hemangioma pericytoma 50 8 R0 Yes Wound complications after
ILP with radiotherapy
a
AWD 65 months
15 PUS 71 12 R0 Yes Wound complications after
ILP with radiotherapy
a
NED 14 months
16 PUS 61 15 R0 Yes Arterial occlusion AWD 17 months
17 Synoviosarcoma 42 18 R1 Yes Local recurrence NED 20 months
18 Liposarcoma 53 37 R0 Yes Local recurrence DOD 110 months
19 Liposarcoma 39 58 R0 No Local recurrence DOD 120 months
20 PNET 56 110 R0 Yes Critical leg ischemia NED 118 months
21 Chondrosarcoma 18 125 R0 Yes Critical leg ischemia NED 134 months
PUS, pleomorphic undiﬀerentiated sarcoma; RT, radiotherapy; NED, no evidence of disease; AWD, alive with disease; DOD, death of
disease; PNET, malignant peripheral nerve sheath tumor; R1 resection, microscopically involved resection margin; ILP, isolated limb
perfusion.
a Patients treated for second ILP with tumor necrosis factor alpha and melphalan.
FIG. 2. Limb salvage curve in patients with locally advanced soft
tissue sarcoma treated with tumor necrosis factor alpha, melpha-
lan, and isolated limb perfusion.
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struction possibilities 2 months after resection of a
local recurrence in the groin (n = 1).
The second time period was within 5 years after
ILP, with two amputations performed for late local
recurrent disease (37 and 58 months after perfusion).
The third episode occurred approximately 10 years
after perfusion. Amputation was performed for crit-
ical leg ischemia with neuropathy due to treatment-
induced atherosclerosis of the remaining tibial artery
that was not suitable for arterial reconstruction (110
and 125 months after perfusion). An example of the
clinical appearance of patient 21 is shown in Fig. 3.
In this patient, a popliteal ILP was performed at the
age of 18 years for a chondrosarcoma. After marginal
resection, this patient received 66 Gy adjuvant
radiotherapy. Ten years after ILP, an amputation
was performed because of critical leg ischemia.
No recurrent disease was found on pathological
examination of the amputated specimen. Another
two patients developed a pathological fracture of the
femur due to radiation-induced osteonecrosis (78 and
129 months after perfusion). These four patients with
late post-ILP complications received high-dose post-
perfusion radiotherapy (60–70 Gy).
Systemic Metastases and Survival
Twelve patients presented with distant metastases
at time of ILP (16% stage IV AJCC); half of these
patients had lung metastases, and the other half had
lymph node metastases. Eleven of these patients died
of disease after a median period of 9 (range 2–54)
months; one patient is alive with no evidence of dis-
ease after 11 months. During follow-up, 25 patients
(36%) developed distant metastases at a median
interval of 9 (range 2–100) months. A statistically
significant difference (P < .001) was observed
between patients with no distant metastases at the
time of ILP compared with patients with metastases
at the time of ILP (Fig. 4). Overall 1, 5, and 10 years
survival for all patients was 82.9% ± 9.2%,
58.7% ± 13.1%, and 42.5% ± 18.2%, respectively
(Fig. 4).
DISCUSSION
The results of a European multicenter trial per-
formed in the 1990s led to the approval of the use of
TNF-a for ILP in patients with locally advanced
extremity sarcomas by the European Medicine
Evaluation Agency.
15 ILP with TNF-a is currently
available in more than 30 centers, and in 2002, a total
of 350 so-called TNF-a perfusions were performed.
As one of the ﬁrst centers that participated in the
FIG. 3. Clinical appearance of lower leg of patient 21 (Table 3)
before amputation for critical leg ischemia.
FIG. 4. Overall survival in patients with locally advanced soft
tissue sarcoma treated with isolated limb perfusion (ILP), tumor
necrosis factor alpha, and melphalan. Statistically signiﬁcant
difference was observed between patients with no distant metas-
tases at time of ILP (mets )) compared with patients with metas-
tases at time of ILP (mets +).
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ades experience, we recently encountered long-term
treatment-related morbidity necessitating amputation
of the perfused limb 10 years after treatment. For this
reason, we analyzed our results of ILP with TNF-a
and melphalan and describe our results in the present
study.
We observed an overall response rate of 82%,
which is in the range of the 63%–91% response rates
reported in the literature.
15,23,25 Although a sugges-
tion has been made for a relation between the grade
of sarcoma and the response to TNF-a ILP, we could
not demonstrate a correlation between grade and the
percentage of necrosis after ILP with TNF-a. This is
in concordance with the results of the Amsterdam
group.
23 Various reports have shown that a limb
salvage rate of 81%–86% can be achieved in patients
with locally advanced limb sarcoma.
15,23,25 An inde-
pendent review committee reconsidered the unresec-
tability criteria of all patients enrolled onto the
European study. Eighty percent of the patients in this
study met the criteria for unresectability, and survival
curves based on a match-control study with cases of
the Scandinavian Soft Tissue Sarcoma Databank
showed that TNF-a ILP had no negative effect on
survival.
26
We used the Kaplan-Meier method to calculate
limb salvage because this method adjusts for censored
observations, i.e., patients who were alive and well at
the time of last contact or patients who died of
distant metastases but who retained preserved limb
function. By use of this method, we calculated a
1-year limb salvage rate of 80%. Amputations were
performed mostly because of postperfusion-related
complications or early local recurrence in the ﬁrst
year after ILP. A second curve in limb salvage was
observed within 5 years after TNF-a ILP in two pa-
tients with late local recurrences. A third bend in the
limb salvage curve was observed approximately
10 years after ILP. This was a new observation in two
patients who had critical leg ischemia with ulceration
and continuous pain. Besides ILP with TNF-a
and melphalan, both patients received adjuvant
radiotherapy (66 and 70 Gy) after marginal tumor
resection.
What seems to be the cause of this late morbidity?
Analysis of the functional and long-term morbidity in
97 patients with stage I melanoma treated with ILP
with melphalan as the sole perfusion agent in our
center showed after a median follow-up of 36 (range
12–76) months, no patients had critical leg ische-
mia.
27 The Rotterdam and Amsterdam perfusion
group reported long-term morbidity consisting of
muscle atrophy or ﬁbrosis in 11% of the patients after
ILP with melphalan; however, cases of critical leg
ischemia are not described.
28 The fact that in our
series no muscle atrophy or ﬁbrosis was found might
be explained by the fact that we always perform a
lateral fasciotomy after ILP to prevent a compart-
ment syndrome. When we performed a literature
search for late morbidity after ILP with TNF-a and
melphalan, no studies could be retrieved.
The clinical importance of late morbidity after
radiotherapy has evolved since Eifel et al.
29 retro-
spectively reviewed the medical records of 1784
FIGO stage IB patients receiving primary radiother-
apy at the M. D. Anderson Cancer Center between
1960 and 1989. She showed that after 5 years, there
was a small but continuous risk of experiencing major
complications of radiotherapy (i.e., urinary, rectal,
and small bowel complications) at up to 20 years of
follow-up. Johansson et al.
30 described a high
occurrence of severe neuropathy closely linked to the
development of ﬁbrosis around the nerve trunks after
aggressive postoperative telecobalt therapy received
in 1963–1965 in a group of 71 patients with breast
cancer who were initially treated with modified
radical mastectomy. Radiotherapy damage to the
vascular system was demonstrated by Hopewell
31 in
an experimental setting; arteries of hamster cheek
pouch showed localized constrictions after irradia-
tion. These constrictions were caused by clones of
endothelial cells and may be the predominant factor
inﬂuencing the degeneration of the capillary bed after
radiotherapy.
32 Evidence of this occlusive effect of
vessels by proliferating endothelial cells after radia-
tion have also been reported by other investigators.
33
Another argument to explain the observed late
morbidity, at least in part, to radiotherapy is the fact
that another two patients who received adjuvant
radiotherapy after ILP with TNF-a and melphalan
developed a pathological fracture of the femur
(78 and 129 months after ILP with TNF-a and mel-
phalan). Radiotherapy-induced osteonecrosis is a
well-known phenomenon. Lin et al.
34 described 12
fractures of the femur after surgery and irradiation
for STS of the thigh. Treatment of these fractures was
difﬁcult and demanding, with only four bony unions
after a mean follow-up of 37 months. When we add
up the evidence of developing ﬁbrosis after ILP with
melphalan and the development of ﬁbrosis after
radiotherapy, the combination of the two regimens
could explain the observed late morbidity rate in the
present series.
Overall survival for all patients showed a steadily
decline, with a 10-year percentage of 42%. Even after
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tases. Sixteen percent of the patients had metastases
at the time of ILP. A marked diﬀerence in survival
was observed when comparing patients with pulmo-
nary or lymph node metastases with patients lacking
metastases at time of ILP. Five-year overall survival
of 59% in this series is higher than the reported 5-year
survival of 48% in the Amsterdam experience
23 and
the reported 32% of Lejeune et al.
24 This is an
unexpected observation because selection criteria for
ILP with TNF-a between the institutes are compa-
rable. High-grade tumors and tumors > 5 cm in
diameter have a great tendency to metastasize.
Patients with such tumors could theoretically beneﬁt
from neoadjuvant chemotherapy. A quantitative
meta-analysis of data from 14 trials of doxorubicin-
based adjuvant chemotherapy showed a beneﬁt from
systemic adjuvant chemotherapy of 6% for local
relapse-free interval, but there was no overall survival
beneﬁt at 10 years.
35 Delaney et al.
36 developed a
regimen of preoperative chemotherapy consisting of
mesna, Adriamycin, ifosfamide, and dacarbazine
(MAID) interspersed with radiotherapy, followed by
resection and postoperative chemotherapy with or
without radiotherapy to improve outcome in patients
with high-grade extremity STS. Compared with a
historical group of control patients, outcome in the
MAID group was better. In an update of 64 patients,
5 required amputation because of disease, 3 had
unresectable disease, and 1 patient refused surgery.
Estimated 3-year survival and local-regional control
were 75.1% and 79.3%, respectively. These results are
comparable with the results of the present study.
37
However, systemic therapy is associated with sys-
temic toxic effects, in contrast with the mild systemic
side effects observed after ILP with TNF-a and
melphalan.
Since 1992, we have not changed the indication for
TNF-a perfusion. Patients who were candidates for
amputation of the involved limb, as assessed by
preoperative magnetic resonance imaging, were
oﬀered an ILP with TNF-a and melphalan, with the
goal of preserving the limb with a locally advanced
STS. After ILP patients received a delayed surgical
resection, adjuvant radiotherapy was provided to
patients with marginal or microscopically positive
resection margins. This treatment resulted in a high
limb salvage rate in patients with locally advanced
STS, although late morbidity can occur, especially
when adjuvant postoperative radiotherapy is applied.
Therefore, continuous follow-up of these patients is
warranted.
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